KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Work In Process (2016 - 2019)

Jazz Pharmaceuticals (JAZZ) has 10 years of Work In Process data on record, last reported at $31.3 million in Q1 2019.

  • For Q1 2019, Work In Process changed N/A year-over-year to $31.3 million; the TTM value through Mar 2019 reached $31.3 million, changed N/A, while the annual FY2018 figure was $26.0 million, 65.91% up from the prior year.
  • Work In Process reached $31.3 million in Q1 2019 per JAZZ's latest filing, up from $26.0 million in the prior quarter.
  • Across five years, Work In Process topped out at $31.3 million in Q1 2019 and bottomed at $11.8 million in Q4 2015.
  • Average Work In Process over 5 years is $20.8 million, with a median of $20.0 million recorded in 2017.
  • Peak YoY movement for Work In Process: dropped 16.04% in 2017, then surged 65.91% in 2018.
  • A 5-year view of Work In Process shows it stood at $11.8 million in 2015, then skyrocketed by 57.9% to $18.7 million in 2016, then decreased by 16.04% to $15.7 million in 2017, then skyrocketed by 65.91% to $26.0 million in 2018, then grew by 20.05% to $31.3 million in 2019.
  • Per Business Quant database, its latest 3 readings for Work In Process were $31.3 million in Q1 2019, $26.0 million in Q4 2018, and $24.0 million in Q2 2018.